Nigeria, bearing a disproportionate global malaria burden, is pioneering a new vaccine rollout initiative.
The R21/Matrix-M vaccine, a significant advancement, boasts a 75% effectiveness rate in clinical trials.
Targeting children aged five to fifteen months, the initial phase focuses on high-risk states like Bayelsa and Kebbi.
While promising, health experts emphasize the continued importance of supplemental malaria prevention strategies.
